Uterine Fibroids: Symptoms, Diagnosis and Treatment

Uterine fibroids — medically termed leiomyomas or myomas — are benign smooth muscle tumours of the uterus. They are the most common benign tumours in women and the most frequent indication for hysterectomy worldwide. Approximately 70% of white women and 80% of Black women will develop fibroids by age 50, though only 20–50% experience symptoms requiring medical attention.

Despite their prevalence, fibroids remain significantly underdiagnosed and undertreated — many women endure years of debilitating heavy menstrual bleeding, pelvic pain, and pressure symptoms, or experience infertility and recurrent pregnancy loss, before receiving a diagnosis. Fibroids are benign — they do not become malignant — but their impact on quality of life, fertility, and reproductive outcomes can be profound.

What Are Fibroids and How Do They Form?

Fibroids arise from a single transformed smooth muscle cell (monoclonal origin) of the uterine myometrium. Each fibroid is a discrete, well-encapsulated nodule of smooth muscle and fibrous tissue, with a characteristic whorled appearance on cut section.

Why fibroids develop:

• Oestrogen and progesterone dependence — fibroids are hormonally driven; they grow during the reproductive years when oestrogen and progesterone are high, and regress after menopause when hormones decline. This is why GnRH agonists (which suppress ovarian hormones) shrink fibroids, and why fibroids never develop before puberty or grow after menopause
• Genetic mutations — somatic mutations in MED12, HMGA2, and ARID1B genes are found in the majority of fibroids; these drive uncontrolled smooth muscle proliferation
• Local growth factors — EGF, IGF-1, and TGF-β amplify oestrogen signalling within fibroids; adipose tissue produces additional oestrogen via aromatase, partly explaining the association with obesity

Types of Fibroids by Location

Location determines symptoms. The FIGO classification defines fibroid types by relationship to the uterine wall:

Type	Location	Symptoms
Submucosal (Type 0–2)	Within or projecting into the uterine cavity	Heavy menstrual bleeding, infertility, pregnancy loss — most symptomatic type
Intramural (Type 3–5)	Within the myometrium	Heavy bleeding, pelvic pressure, bulk symptoms; may distort cavity
Subserosal (Type 6–7)	Projecting outward from uterine surface	Pelvic pressure, bladder/bowel symptoms; rarely affects bleeding
Pedunculated	Attached by a stalk (intracavitary or exophytic)	May prolapse through cervix; torsion risk (exophytic)
Cervical	Within cervical stroma	May cause obstruction, difficult delivery

Multiple fibroids of mixed types are common — the uterus may contain dozens of fibroids of varying sizes.

Risk Factors

• Age — prevalence rises with age; peak incidence in the perimenopausal 40s
• Black African/Caribbean ethnicity — 2–3× higher incidence; earlier onset; larger and more numerous fibroids; higher symptom burden; less response to conservative management
• Family history — first-degree relative with fibroids significantly increases risk
• Obesity — increased peripheral aromatisation of androgens to oestrogen
• Early menarche — longer lifetime oestrogen exposure
• Nulliparity — pregnancy is protective (progesterone dominant environment, reduced uterine distension)
• Diet — red meat, processed foods, vitamin D deficiency associated with higher risk; green vegetables possibly protective

Oral contraceptives and the levonorgestrel IUS are not risk factors and may actually reduce fibroid growth.

Symptoms

Heavy Menstrual Bleeding (HMB)

The most common and impactful symptom — particularly with submucosal fibroids. HMB is defined as blood loss interfering with quality of life. Features of fibroid-related HMB:

• Prolonged periods (>7 days)
• Passage of large clots
• Flooding (sudden loss of blood requiring urgent toilet access)
• Changing pads/tampons every 1–2 hours
• Iron deficiency anaemia — chronic blood loss; fatigue, breathlessness, pallor; frequently severe (haemoglobin <80 g/L in some women)

Pelvic Pressure and Bulk Symptoms

From large fibroids or subserosal fibroids:

• Urinary frequency and urgency — bladder compression; urinary retention in rare cases (large anterior fibroid compressing urethra)
• Constipation and rectal pressure — posterior fibroid compressing rectum
• Abdominal distension — uterus enlarged to the point of visible abdominal protrusion; a uterus enlarged to 20-week size by fibroids is not unusual
• Lower back and pelvic pain — pressure on pelvic nerves and vessels

Dysmenorrhoea

Painful periods — from uterine cramping to expel blood/clots, or from submucosal fibroids causing uterine contractions.

Subfertility and Reproductive Complications

Fibroids affect fertility in several ways:

• Submucosal fibroids — distort the uterine cavity; interfere with implantation; associated with recurrent miscarriage and reduced IVF success rates; removal improves outcomes
• Intramural fibroids (>3–4 cm) — distort the cavity; impair sperm transport; reduce uterine blood flow
• Pregnancy complications: preterm labour, malpresentation, placental abruption, postpartum haemorrhage, caesarean section; fibroid growth during pregnancy (particularly first trimester) may cause acute red degeneration — sudden severe pain from infarction of a rapidly enlarging fibroid

Fibroid Degeneration

Fibroids outgrow their blood supply — necrosis and degeneration cause acute severe pelvic pain, fever, and tenderness (red degeneration — haemorrhagic infarction, common in pregnancy). Usually managed conservatively.

Diagnosis

Pelvic Ultrasound

The primary investigation — transvaginal ultrasound (TVUS) provides the best image quality. Accurately identifies fibroid number, location, size, and uterine volume. Essential for initial diagnosis, treatment planning, and monitoring response to medical therapy.

Saline-infusion sonography (SIS / sonohysterography) — saline injected into the uterine cavity enhances delineation of submucosal fibroid relationship to the cavity; important for pre-surgical planning.

MRI Pelvis

The gold standard for fibroid mapping — superior to ultrasound for defining fibroid number, precise location, and relationship to the endometrium; essential before myomectomy (surgical planning) and uterine artery embolisation (UAE). Also distinguishes fibroids from adenomyosis (diffuse uterine enlargement without discrete nodules) — the two conditions frequently coexist and require different management.

Hysteroscopy

Direct visualisation of the uterine cavity — identifies and characterises submucosal fibroids; simultaneously allows resection (hysteroscopic myomectomy). Essential for evaluating cavity distortion before fertility treatment.

Investigations for HMB

• Full blood count: assessment of anaemia severity (haemoglobin, ferritin)
• Endometrial biopsy: in women over 45, or with abnormal bleeding pattern, to exclude endometrial hyperplasia or carcinoma as a concurrent cause

Treatment

Treatment choice depends on symptom severity, fibroid size and location, desire for future fertility, proximity to menopause, and patient preference.

Medical Management

Levonorgestrel Intrauterine System (LNG-IUS / Mirena)

First-line medical treatment for heavy menstrual bleeding with fibroids — reduces menstrual blood loss by 70–95%; controls dysmenorrhoea. Limited efficacy for large cavity-distorting fibroids (may be expelled). Does not shrink fibroids but very effective for symptom control in appropriate cases.

Tranexamic Acid / NSAIDs

Non-hormonal options for HMB: tranexamic acid (antifibrinolytic) taken during menstruation reduces blood loss by approximately 50%; NSAIDs reduce prostaglandin-driven blood loss and dysmenorrhoea. Suitable for women seeking to preserve fertility without hormonal methods.

Combined Oral Contraceptive Pill / Progestogens

Regulate cycle and reduce menstrual loss; do not shrink fibroids but manage bleeding symptoms; useful in perimenopausal women or those with cycle irregularity.

GnRH Agonists (Leuprorelin, Goserelin, Nafarelin)

Suppress pituitary gonadotropin release → profound oestrogen deficiency → fibroid shrinkage (typically 35–65% volume reduction) and amenorrhoea. Used primarily:

• Pre-operatively (2–3 months before myomectomy or hysterectomy): shrinks fibroids and uterus, reduces intraoperative blood loss, corrects anaemia
• Bridge to menopause: for perimenopausal women
• Side effects: menopausal symptoms (hot flushes, bone loss), cannot be used >3–6 months without add-back HRT

Ulipristal Acetate (Esmya)

Selective progesterone receptor modulator — causes fibroid shrinkage (~50%) and amenorrhoea; pre-operative or intermittent course treatment. Regulatory status varies by country; hepatotoxicity concerns have restricted use in some jurisdictions.

Linzagolix / Relugolix (Oral GnRH Antagonists)

New once-daily oral options with add-back hormonal therapy — sustained fibroid symptom control; avoid menopausal side effects; approved/approving in EU and US.

Surgical Treatments

Hysteroscopic Myomectomy

Removal of submucosal fibroids via the uterine cavity — a resectoscope is passed through the cervix; the fibroid is resected in chips using electrocautery. No abdominal incisions required; day-case or overnight procedure.

• Curative for submucosal fibroids; resolves HMB in >90%
• Fertility is preserved; required before IVF when cavity is distorted
• Limited to fibroids that significantly protrude into the cavity (FIGO Type 0–1–2)

Laparoscopic Myomectomy

Minimally invasive surgical removal of fibroids through laparoscopic ports. Fibroids are excised from the myometrium and removed via morcellation (contained power morcellator inside a bag, or manual morcellation through extended port site).

• Preferred for women wishing to preserve the uterus and fertility
• Recovery faster than open surgery (1–2 weeks vs 4–6 weeks)
• Technical limits: very large fibroids (>8–10 cm), multiple (>3–5) fibroids — may require conversion to open
• Uterine scar integrity for future pregnancy is a consideration — myomectomy creates a uterine scar; caesarean section often recommended for subsequent delivery

Open (Laparotomy) Myomectomy

For large, multiple, or complex fibroids beyond laparoscopic limits; allows greatest surgical access; higher blood loss; longer recovery.

Hysterectomy

Definitive treatment — removes the uterus (and fibroids). The only guaranteed permanent cure. Indicated for:

• Severe symptoms not responding to conservative/surgical treatment
• Women who have completed childbearing and prefer definitive treatment
• Very large uteri

Total hysterectomy (removes uterine body and cervix) vs subtotal (preserves cervix) — no proven advantage to preserving cervix in most cases. Laparoscopic or robot-assisted hysterectomy standard at experienced centres; vaginal hysterectomy for appropriately sized mobile uteri.

Uterine Artery Embolisation (UAE)

Interventional radiology procedure — under local anaesthesia, a catheter is passed via the femoral artery into the uterine arteries bilaterally; tiny particles (polyvinyl alcohol microspheres) are injected to block blood flow to fibroids. Fibroids infarct and shrink (~50% volume reduction); HMB and bulk symptoms improve in 80–90% of women.

• Preserves the uterus; no surgical incisions; 1–2 night inpatient; 1–2 week recovery
• Suitable for symptomatic multiple fibroids in women who do not wish surgery
• Fertility: UAE is generally not recommended in women desiring pregnancy — risk of ovarian failure (ovarian artery embolisation), uterine ischaemia, and placentation abnormalities; myomectomy preferred for fertility
• Failure rate approximately 10–15%; 20% require further intervention within 5 years

Focused Ultrasound Surgery (MRI-guided HIFU / ExAblate)

High-intensity focused ultrasound destroys fibroid tissue by thermal ablation without incisions — performed inside an MRI scanner; non-invasive; outpatient. Suitable for selected anterior fibroids with good MRI characteristics; growing evidence base; available at specialist centres.

Uterine Fibroid Care in China

China's gynaecology centres offer:

• Comprehensive fibroid assessment: transvaginal ultrasound, saline infusion sonography, and MRI pelvis; precise FIGO classification and treatment planning
• Hysteroscopic myomectomy: specialist hysteroscopy teams; same-day or overnight procedure; outpatient approach for appropriate submucosal fibroids
• Laparoscopic myomectomy: minimally invasive fibroid removal; experienced laparoscopic gynaecological surgeons
• Uterine artery embolisation: interventional radiology teams performing UAE for symptomatic fibroids; 1–2 night inpatient
• MRI-guided HIFU: non-invasive focused ultrasound treatment available at specialist centres in China — one of the world leaders in HIFU deployment
• GnRH agonist and oral GnRH antagonist therapy: pre-operative fibroid shrinkage and anaemia correction
• Cost: care in China is generally less expensive than UK private treatment, but the hospital prices each case individually — ask us for the written quote before you commit.
• Full English care navigation from diagnosis through medical, surgical, or interventional treatment

Contact a ChinaMedicalTour care navigator to arrange a fibroid assessment, hysteroscopy, or myomectomy consultation.

---

Medical content based on MSD Manuals and international uterine fibroid guidelines (ESHRE, ACOG, NICE). Evidence reviewed 2025.

Frequently Asked Questions

Can foreign patients submit pelvic imaging and gynecology reports for specialist review?

Yes. Pelvic MRI scans, transvaginal ultrasound reports, and histopathology results can be submitted for remote pre-consultation review by experienced Chinese gynecologists.

What surgical and minimally invasive treatments are offered for gynecological conditions in China?

Chinese centers evaluate laparoscopic and hysteroscopic myomectomy, excision of endometriosis, uterine artery embolization, and fertility-preserving surgical interventions.

How is care navigation handled for international gynecological patients?

China Medical Tour provides non-clinical coordination including appointment booking, on-site hospital escort, translation assistance, and certified medical documentation upon completion.